New Protein Study Could Mean Novel Treatment Option for Some Mesothelioma Patients, According to Surviving Mesothelioma

Share Article

Scientists say a protein that prevents the immune system from fighting cancer may be a new target for mesothelioma treatment.

Study Links Protein with Mesothelioma Prognosis

Protein Could be Target for Mesothelioma Treatment

The results of our study could offer new treatment to this population of patients...

Cancer researchers in Spain have presented their findings on PD-L1, a protein that suppresses the body’s anti-tumor response. As Surviving Mesothelioma reports, the research team says targeting this protein could offer a new way to combat mesothelioma. Click here to read the full story.

Doctors at Vall d’Hebron Institute Oncology in Barcelona, Spain say PD-L1 was present in 20 percent of the 119 mesothelioma patients they tested.

"The results of our study could offer new treatment to this population of patients, identifying a subset of malignant pleural mesothelioma patients who expressed PD-L1 and could be treated with targeted therapies to PD-L1," writes investigator Dr. Susana Cedres.

The study, presented at this year’s European Society of Medical Oncology (ESMO) Conference in Barcelona, Spain, found that mesothelioma patients who expressed PD-L1 had a much shorter survival time than patients who did not.

“Although only a limited number of mesothelioma patients express this particular protein, this study illustrates why immunotherapy is considered one of the most promising new approaches for mesothelioma and other cancers,” says Alex Strauss, Managing Editor of Surviving Mesothelioma.

To read more about the study’s findings and the role that PD-L1 may play in mesothelioma prognosis, see Protein Discovery Could Open Door to New Treatment for 1 in 5 Mesothelioma Patients, now available on the Surviving Mesothelioma website.

Cedres, S et al, “15560 PR – Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma, European Society of Medical Oncology (ESMO) 2014 Conference, Barcelona, Spain,

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website